Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio Plc LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.50 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
0.40 0.55
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.19 -1.51 3
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.50 GBX

Motif Bio (MTFB) Latest News

More Motif Bio News
Motif Bio Investors    Motif Bio Takeover Rumours

Motif Bio (MTFB) Discussions and Chat

Motif Bio (MTFB) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Motif Bio trades in real-time

Motif Bio (MTFB) Top Chat Posts

Motif Bio Daily Update: Motif Bio Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTFB. The last closing price for Motif Bio was 0.50p.
Motif Bio Plc has a 4 week average price of 0p and a 12 week average price of 0p.
The 1 year high share price is 1.75p while the 1 year low share price is currently 0.04p.
There are currently 654,991,023 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Motif Bio Plc is £3,274,955.12.
moneymunch: RNS Number : 4269Q Motif Bio PLC 26 February 2021 Motif Bio plc ("Motif" or the "Company") Update re Motif BioSciences Inc Motif Bio plc (AIM: MTFB), which has been reclassified as an AIM Rule 15 cash shell, provides an update regarding its wholly owned subsidiary, Motif BioSciences Inc. ("Motif Inc"), following the announcements of 28 January and 18 March 2020. Motif announces that it has entered into a Stock Purchase Agreement (the "SPA") with Orange Avenue Technologies, LLC ("Orange") pursuant to which Orange has acquired 100 per cent. of the outstanding shares of Motif Inc from Motif with immediate effect (the "Transaction"). Orange is wholly owned by John Palmer, the President of Tamarack Associates Inc. ("Tamarack"), the company which was engaged by Motif to facilitate the sale of iclaprim and other assets of Motif Inc in January 2020. Key Terms of the Transaction As consideration for the Transaction, Motif will receive the nominal amount of US$1 in addition to an interest in revenue that is derived from Motif Inc's iclaprim asset. Pursuant to the terms of the SPA, if Motif Inc generates revenue from the iclaprim asset above its outstanding liabilities, Motif Inc shall retain the first US$250,000 in revenue and thereafter, 90 per cent of any additional revenue will be paid to the Company, and the remaining 10 per cent of any additional revenue will be retained by Motif Inc. The Transaction completes the orderly sale of Motif Inc's operations, which was first announced on 25 October 2019. Update re Proposed Reverse Takeover Motif remains suspended from trading while the proposed reverse takeover pursuant to AIM Rule 14 (the "Reverse Takeover"), which was referred to in the Company's announcements dated 5 January and 27 January 2021, is negotiated and advanced. The Company's Directors look forward to providing shareholders with further updates regarding the Reverse Takeover as appropriate. Jonathan Gold, Motif's President and Chief Business Officer, commented: "The Transaction is an important step to prepare Motif to complete the Reverse Takeover. The Transaction also creates incentives for Orange to focus on the potential generation of value from iclaprim for Motif's shareholders, while allowing Motif to focus on completing the Reverse Takeover with a UK-based ADC (Antibody-Drug Conjugate) discovery and development company." Related Party Transaction John Palmer, as President of Tamarack, was appointed as the sole Executive Officer of Motif Inc on 28 January 2020. As Motif Inc was a wholly owned subsidiary of Motif prior to the Transaction and Orange and Tamarack are both majority owned by John Palmer, John Palmer and Orange are deemed to be related parties of Motif. As such, the Transaction constitutes a related party transaction in accordance with Rule 13 of the AIM Rules for Companies. Motif's Directors consider, after consultation with the Company's Nominated Adviser, that the terms of the Transaction are fair and reasonable, in so far as the Company's shareholders are concerned. The person responsible for the release of this announcement on behalf of Motif is Jonathan Gold, President and Chief Business Officer.
scottdavid70: First time project vs something that’s been done thousands of times - there was no reason for a delay unless the liver issue was suddenly realised then. Many of us invested here feel that’s when the issue first surfaced- the following actions - cancelled HABP and European submission stopped suggest this. Plus they did countless conferences and not once did the data presented move the share price. If the data was so compelling why didn’t anyone buy in? Something strange in the neighbourhood!!!
perfectstorm: Not long to wait now. You will soon see that there is no RTO, never was never will be end of story. The whole thing is smoke and mirrors to make you think that the BOD are doing something useful with their time.It is actually sad to see all this talk of what the share price will be. Here is what it will be £0.00. get that into your dreamers heads.
scottdavid70: I know many don’t read RNS’s properly or understand the process and are expecting news soon but this is Greedy Graham Legacy company nod the Gold(en) touch has rubbed off on Jon in terms of salary enhancing their bank balances despite the company being de-listed and a share price which was decimated to 0.01p at one stage from its high of 70p
scottdavid70: Just look at LSE celebrating like Covid has vanished into thin air. Thats what these people, these Board members, these Directors who have destroyed the share price now bank on is the ecstasy of something no matter the pittance it will be for especially long term shareholders but also for even medium term those with averages of 1p let alone some who may still be sitting on 20p plus averages. They are banking on human nature. No patience they have taken this long for a reason, desperation had set it so the relief there maybe something is in the air and palpable. Hope over despair mainly though is the emotional trade they have made here. LSE popping champagne corks Well I believe there are enough shareholders whom dont want to lose virtually everything to just have to sit and watch Glumsden and Gold ride off into the sunset with in our view unearned money. So they would rather let Lumsden and Gold know what it feels to lose the lot like we have pretty much felt for 2 years
moneymunch: RNS Number : 9727M Motif Bio PLC 27 January 2021 Motif Bio plc ("Motif" or the "Company") Update re proposed Reverse Takeover Motif Bio plc (AIM: MTFB), which has been reclassified as an AIM Rule 15 cash shell, provides a further update regarding the proposed reverse takeover pursuant to AIM Rule 14 ("Reverse Takeover") that was outlined in the Company's announcement of 5 January 2021. Motif announces that it continues to progress a Reverse Takeover under a Heads of Terms Agreement ("HOT") with a UK based candidate in the healthcare sector (the "Target"), as a result of which, subject to, among other matters, the execution of a Sale and Purchase Agreement (the "SPA"), Motif would acquire the entire issued share capital of the Target (the "Proposed Transaction"). Motif will remain suspended from trading while the Proposed Transaction is negotiated and advanced, and the Company will provide shareholders with further updates as appropriate. The Target The Target is a UK-based ADC (Antibody-Drug Conjugate) discovery and development company, which uses front-line clinical experience to develop next generation therapeutics for the treatment of various cancers. The Proposed Transaction The Proposed Transaction will be classified as a Reverse Takeover. Completion of the Proposed Transaction is therefore subject to certain matters including the completion of an appropriate SPA, approval by Motif's shareholders at a general meeting to be convened in due course ("General Meeting"), the raising of an appropriate level of equity (the "Fundraising") to accelerate the Target's development programmes, the grant of a Rule 9 waiver by the UK Takeover Panel ("Rule 9 Waiver") in respect of the proposed issue of new shares to the Target and the admission of the enlarged group to trading on AIM. In order to convene the General Meeting, the Company is required to publish an AIM Admission Document which details, inter alia, the terms of the Proposed Transaction. As per the HOT, consideration for the Proposed Transaction will be paid in ordinary shares of Motif. In addition to the Fundraising, it is intended that the Company will carry out an appropriate share consolidation and that Motif will change its name. Should the Proposed Transaction proceed, it is currently expected that the AIM Admission Document will be published before the end of March 2021. At present there can be no assurances that Motif will be able to complete the Proposed Transaction and as a consequence the Company's admission to trading on AIM may be cancelled. The AIM Admission Document will include a Technical Expert's report which is being prepared in respect of the Target's technology and assets. Jonathan Gold, Motif's President and Chief Business Officer, commented: "The Motif Directors are encouraged by the way the Proposed Transaction is progressing and I look forward to providing our shareholders with further updates and additional information regarding the Target in due course."
petersmith6: The directors will get a share deal.. do think they will want the share price to go down or UP.
scottdavid70: 18 December 2018 Clinical stage bio company Motif Bio could see its share price surge early next year, argued Peel Hunt, with the US FDA due to give possible approval to Motif's antibiotic iclaprim on 13 February. Trading at 26p, Peel Hunt is targeting 95p. There they were again - Peel Hunt Wrong then and more than likely wrong choice for the company now but they know the skeletons so an easy choice maybe?
scottdavid70: 1) charge satisfied at companies house no RNS = no value for shareholders of Motif otherwise a RNS must be issued if it is to have a material impact on the Share Price 2) Patent issued no RNS = no value for shareholders of Motif otherwise a RNS must be issued if it is to have a material impact on the Share Price Pretty simple really - call Walbrook Monday and they will explain. No last minute news before the AGM to save Lumsden. The vote is happening and they have currently achieved zero for shareholders these past 18 months as far as we have been told officially.
moneymunch: Fair enough Lionheart, not many shares go up in a straight line but MTFB certainly has had a couple of goes, and so consequently you're always going to get profit takers to bring the share price down, and also a determined effort by the sharebashers, mostly on Lse who have been relentless to deter and discourage. They're either betting short or more likely working to get the price down for the very large buys that we've seen. Lombard's holds 16.85% and the 12.5m buy after close on Friday suggests another TR1 in the pipeline. I'm personally expecting a big bounce next week and if the share bashers are quiet, then we'll know their job is done, a TR1 will drop and the share price will.advance in anticipation of RTO news, which obviously gets closer every day. Gl :-)
Motif Bio share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Motif Bio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210306 09:25:34